2024-ASC-STUDENT
23.4.2024 09:03:33 CEST | Business Wire | Press release
On April 13, 2024, the 2024 ASC Student Supercomputer Challenge (ASC24) Finals drew to a close at Shanghai University after five days of intense competition. Peking University emerged as the undisputed overall champion, securing their place in ASC Student Supercomputer Challenge history.
After ASC24 registration opened on November 16, 2023, over 300 teams from universities participated in the intense preliminary contests. As a result, the absolute best 25 teams ascended to the finals hosted at Shanghai University from April 9 to 13, 2024. This marked a groundbreaking moment in ASC history, with the highest number of teams ever qualifying for onsite finals since the competition's inception in 2012.
During the finals, teams showcased their skills by designing and building cluster systems capped at a maximum power consumption of 3,000 W. They tackled a lineup of cutting-edge scientific and engineering applications, including HPL and HPCG benchmarks, Large Language Model (LLM), OpenCAEPoro, GoMars, and WannierTools. ASC24 featured again a group competition in which 25 teams, divided into 5 groups, explored the real-world application of ParaSeis. They simulated seismic wave propagation and refined algorithms through collaborative communication.
The competition reached its pinnacle when Peking University ultimately seized the coveted Champion title. Their performance not only impressed everyone but also demonstrated exceptional proficiency across various tasks such as GoMars, LLM, and WannierTools. This showed their expertise and unequaled mastery of comprehensive supercomputing systems, applications, and top-tier optimization skills.
The National Tsing Hua University team achieved significant results with the OpenCAEPoro task. They maximized the use of computing resources, executed large-scale parallel optimization of OpenCAEPoro while navigating power consumption constraints, and achieved the shortest run time, securing them the prestigious e Prize.
A collaborative effort led by Shanghai University, in partnership with the Southern University of Science and Technology, Qilu University of Technology, Southwest Petroleum University, and Hong Kong Polytechnic University, achieved remarkable optimization of ParaSeis. Their commendable teamwork and dedication were duly recognized with the prestigious Group Competition Award.
Additionally, the Zhejiang University team secured the Highest LINPACK Award, showcasing their exceptional computational prowess. Meanwhile, the outstanding performances of Shanxi University and Shanghai Jiao Tong University were properly honored with the coveted Application Innovation Award, recognizing their innovative contributions to the field.
Jack Dongarra, a distinguished member of the US National Academy of Engineering and recipient of the prestigious Turing Award, as well as a Distinguished Professor at both Oak Ridge National Laboratory and the University of Tennessee, and Chair of the ASC Advisory Committee, shared his insights during the closing ceremony of the ASC24 Finals: "ASC challenges and inspires the next generation of HPC scientists and engineers to deliver innovative solutions using the most cutting-edge technologies. The competition has been described as the world’s largest supercomputing hackathon, striving to foster the next generation of young talents to inspire exploration, innovation, and collaboration in Supercomputing and AI."
About ASC
The ASC Student Supercomputer Challenge stands as the globe's premier student supercomputer competition, with the generous support of experts and institutions spanning Asia, Europe, and America. ASC boasts a noble mission: to foster the exchange and cultivation of young supercomputing talent across borders, enhance supercomputing applications and research and development capabilities, propel the advancement of supercomputing technologies, and stimulate technical and industrial innovation. Since its inception in 2012, the ASC Student Supercomputer Challenge has grown every year, attracting over 10,000 undergraduates from every corner of the planet. To discover more about this impactful endeavor, visit the website.
http://www.asc-events.net/StudentChallenge/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423424820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
